Observations placeholder
Letrozole and Femara
Identifier
017655
Type of Spiritual Experience
Number of hallucinations: 53
Background
A description of the experience
Letrozole (INN, trade name Femara) is an oral non-steroidal aromatase inhibitor for the treatment of hormonally-responsive breast cancer after surgery.
Letrozole is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women.
Letrozole has been used ‘off label’ for ovarian stimulation by fertility doctors since 2001 because it has fewer side-effects than clomiphene (Clomid) and less chance of multiple gestation.
On Jan, 11, 2017 5,433 people reported to have side effects when taking Letrozole.
Among them, 8 people (0.15%) have Hallucination
On Dec, 23, 2016 10,408 people reported to have side effects when taking Femara.
Among them, 45 people (0.43%) have Hallucination
Time on Femara when people have Hallucination :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Hallucination | 20.00% | 20.00% | 0.00% | 20.00% | 0.00% | 40.00% | 0.00% |
On Aug, 10, 2015: 8,436 people reported to have side effects when taking Femara. Among them, 508 people (6.02%) have Death.
Time on Femara when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 8.16% | 36.73% | 24.49% | 14.29% | 16.33% | 0.00% | 0.00% |
Age of people who have Death when taking Femara :
| 0-1 | 2-9 | 10-19 | 20-29 | 30-39 | 40-49 | 50-59 | 60+ | |
| Death | 0.00% | 0.00% | 0.00% | 0.30% | 0.90% | 9.58% | 28.14% | 61.08% |